Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
25 hedge funds and large institutions have $648K invested in Orion Biotech Opportunities Corp. Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 3 closing their positions.
14% less funds holding
Funds holding: 29 → 25 (-4)
71% less capital invested
Capital invested by funds: $2.25M → $648K (-$1.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGC
Angelo Gordon & Co
New York
|
-$15.7K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$4.18K |
| 3 |
SC
Sculptor Capital
New York
|
-$3.17K |
| 4 |
FIG
Fortress Investment Group
New York
|
-$2.86K |
| 5 |
GAM
Gritstone Asset Management
Bethesda,
Maryland
|
-$2.16K |
ORIAW Hedge Fund Activity: Q1 2023 in Review
25 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q1 2023, worth a combined $648K — down 71% from $2.25M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ORIAW and 0 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 0 added.
The largest seller was Angelo Gordon & Co, exiting entirely with an estimated $15.7K sold.
- 25 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q1 2023, down from 29 in Q4 2022.
- Funds reported $648K of Orion Biotech Opportunities Corp. Warrant stock for Q1 2023, down 71% quarter-over-quarter.
- 0 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q1 2023 and 3 closed out, a net change of -3 holders.
- The largest Orion Biotech Opportunities Corp. Warrant seller in Q1 2023 was Angelo Gordon & Co, an estimated $15.7K sold.
Based on aggregated 13F filings for Q1 2023.